Hansoh Pharmaceutical (HKG:3692) has obtained drug registration approval for an additional indication of Ameile from China's National Medical Products Administration, a May 9 Hong Kong bourse filing said.
The new indication, which is the fourth indication of Ameile to be approved, is for the adjuvant treatment of adult patients with stage II to IIIB non-small cell lung cancer